144 related articles for article (PubMed ID: 34919788)
1. p53 mutations define the chromatin landscape to confer drug tolerance in pancreatic cancer.
Zampieri C; Panatta E; Corbo V; Mauriello A; Melino G; Amelio I
Mol Oncol; 2022 Mar; 16(6):1259-1271. PubMed ID: 34919788
[TBL] [Abstract][Full Text] [Related]
2. NUAK2 and RCan2 participate in the p53 mutant pro-tumorigenic network.
Mammarella E; Zampieri C; Panatta E; Melino G; Amelio I
Biol Direct; 2021 Aug; 16(1):11. PubMed ID: 34348766
[TBL] [Abstract][Full Text] [Related]
3. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis.
Tang J; Feng Y; Kuick R; Green M; Green M; Sakamoto N; Kurosu Y; Lin J; Cho KR; Fearon ER
Lab Invest; 2019 Oct; 99(10):1454-1469. PubMed ID: 31148594
[TBL] [Abstract][Full Text] [Related]
4. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis.
Heinlein C; Krepulat F; Löhler J; Speidel D; Deppert W; Tolstonog GV
Int J Cancer; 2008 Apr; 122(8):1701-9. PubMed ID: 18092324
[TBL] [Abstract][Full Text] [Related]
6. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.
Zhu J; Sammons MA; Donahue G; Dou Z; Vedadi M; Getlik M; Barsyte-Lovejoy D; Al-awar R; Katona BW; Shilatifard A; Huang J; Hua X; Arrowsmith CH; Berger SL
Nature; 2015 Sep; 525(7568):206-11. PubMed ID: 26331536
[TBL] [Abstract][Full Text] [Related]
7. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells.
Pfister NT; Fomin V; Regunath K; Zhou JY; Zhou W; Silwal-Pandit L; Freed-Pastor WA; Laptenko O; Neo SP; Bargonetti J; Hoque M; Tian B; Gunaratne J; Engebraaten O; Manley JL; Børresen-Dale AL; Neilsen PM; Prives C
Genes Dev; 2015 Jun; 29(12):1298-315. PubMed ID: 26080815
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 in colon cancer.
Nakayama M; Oshima M
J Mol Cell Biol; 2019 Apr; 11(4):267-276. PubMed ID: 30496442
[TBL] [Abstract][Full Text] [Related]
10. Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours.
Dhaka B; Sabarinathan R
BMC Cancer; 2021 Jun; 21(1):669. PubMed ID: 34090364
[TBL] [Abstract][Full Text] [Related]
11. Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation.
van Miltenburg MH; van Nimwegen MJ; Tijdens I; Lalai R; Kuiper R; Klarenbeek S; Schouten PC; de Vries A; Jonkers J; van de Water B
Br J Cancer; 2014 May; 110(11):2747-55. PubMed ID: 24809783
[TBL] [Abstract][Full Text] [Related]
12. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression.
Amelio I; Mancini M; Petrova V; Cairns RA; Vikhreva P; Nicolai S; Marini A; Antonov AA; Le Quesne J; Baena Acevedo JD; Dudek K; Sozzi G; Pastorino U; Knight RA; Mak TW; Melino G
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10869-E10878. PubMed ID: 30381462
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
14. p53 gain-of-function mutations increase Cdc7-dependent replication initiation.
Datta A; Ghatak D; Das S; Banerjee T; Paul A; Butti R; Gorain M; Ghuwalewala S; Roychowdhury A; Alam SK; Das P; Chatterjee R; Dasgupta M; Panda CK; Kundu GC; Roychoudhury S
EMBO Rep; 2017 Nov; 18(11):2030-2050. PubMed ID: 28887320
[TBL] [Abstract][Full Text] [Related]
15. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
Barta JA; Pauley K; Kossenkov AV; McMahon SB
Carcinogenesis; 2020 Mar; 41(1):67-77. PubMed ID: 31067569
[TBL] [Abstract][Full Text] [Related]
16. PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer.
Xia W; Bai H; Deng Y; Yang Y
J Cell Mol Med; 2020 Nov; 24(21):12642-12655. PubMed ID: 32985124
[TBL] [Abstract][Full Text] [Related]
17. The Crusade against Mutant p53: Does the COMPASS Point to the Holy Grail?
Abraham CG; Espinosa JM
Cancer Cell; 2015 Oct; 28(4):407-408. PubMed ID: 26461087
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
Kang HJ; Chun SM; Kim KR; Sohn I; Sung CO
PLoS One; 2013; 8(8):e72609. PubMed ID: 23967324
[TBL] [Abstract][Full Text] [Related]
19. p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer.
Butera A; Roy M; Zampieri C; Mammarella E; Panatta E; Melino G; D'Alessandro A; Amelio I
Biol Direct; 2022 Mar; 17(1):6. PubMed ID: 35255936
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 antagonizes p63/p73-mediated tumor suppression via Notch1.
Zhang J; Sun W; Kong X; Zhang Y; Yang HJ; Ren C; Jiang Y; Chen M; Chen X
Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24259-24267. PubMed ID: 31712410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]